Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: racine and nonhuman primates.

@article{Yang2004EfficacyAS,
  title={Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: racine and nonhuman primates.},
  author={Wen Qing Yang and Xueqing Lun and Cheryl A Palmer and MarkH. Wilcox and Huong Muzik and Zhong Qiao Shi and Richard H Dyck and Matt Coffey and Brad Lee Thompson and Mark L. Hamilton and Sandra G. Nishikawa and Penny M A Brasher and Kevin Fonseca and David Lewis George and N Berry Rewcastle and Randal N Johnston and D. P. Stewart and Patrick Wing Kwong Lee and Donna Lorraine. Senger and Peter A. J. Forsyth},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2004},
  volume={10 24},
  pages={
          8561-76
        }
}
PURPOSE Human reovirus type 3 has been proposed to kill cancer cells with an activated Ras signaling pathway. The purpose of this study was to investigate the efficacy of reovirus in immunocompetent glioma animal models and safety/toxicity in immunocompetent animals, including nonhuman primates. EXPERIMENTAL DESIGN Racine glioma cells 9L and RG2 were implanted s.c. or intracranially in Fisher 344 rats with or without reovirus antibodies, followed by treatment of reovirus. To study whether… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 35 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 53 REFERENCES

Reovirus as an oncolytic agent against experimental human malignant gliomas.

  • Journal of the National Cancer Institute
  • 2001
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

A phase I clinical trial evaluating intralesional Reolysin (reovirus) in histologically confirmed malignancies

D Morris, PA Forsyth, AH Paterson
  • Proc Am Soc Clin Oncol Annu Meet 2002;21:92:24
  • 2004
VIEW 1 EXCERPT